TD Cowen keeps a Buy rating and $80 price target on CVS. The firm says the DOJ complaint relating to opioid prescriptions is incremental to the 2022 settlement with state and local governments for $5B over 10 years. The multi-year impasse between the DOJ and CVS suggests CVS is confident in its case, and while it is unclear what a final settlement figure may be, it may be a fraction of the $5B 10-year settlement that CVS came to with state and local governments in 2022, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Republicans spending package includes no PBM reform, Punchbowl says
- CVS Health price target lowered to $63 from $77 at BofA
- DoJ accuses CVS of filling, billing government for illegal opioid prescriptions
- CVS Health price target lowered to $51 from $57 at Leerink
- Trump Trade: Analyst says Trump win ‘not as positive as you’d think’ for Tesla